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Will Stents of New Technology Replace 
Coronary Artery Bypass Surgery?
Manolis Vavuranakis, MD
A B S T R A C T
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention 
(PCI) are commonly used procedures to treat patients with multi-vessel coronary ar-
tery disease requiring myocardial revascularization. In the past, several randomized 
comparisons between bypass surgery and coronary angioplasty were performed but 
had the limitation of comparing CABG to balloon angioplasty. These studies, per-
formed in the pre-stent era, showed no significant differences in mortality and non-
fatal myocardial infarction between patients treated with surgery versus PCI. Surgery 
had an advantage only in treated diabetic patients. More recently, in the stent era, 
new randomized comparisons between PCI and bypass surgery have been performed. 
The long-term follow-up data of the four randomized trials of PCI using bare metal 
stents versus CABG (Stent or Surgery trial, Artery Revascularization Therapies 
Study [ARTS], ERACI II, and Medicine, Angioplasty, or Surgery Study [MASS] II) 
showed similar incidence in the combined death, non-fatal myocardial infarction, and 
stroke rate with both revascularization techniques. However, contemporary treatment 
of coronary artery disease with stents has switched to the use of drug eluting stents. In 
a manner similar to the impact of bare-metal stents compared with non-stent balloon 
angioplasty, drug-eluting stents further reduce restenosis. Data from ARTS II sup-
port further reduction in need for repeat interventions in the stent group. During the 
time since these studies were initiated, CABG procedures have undergone also pro-
gressive improvement. The effects of PCI with drug-eluting stents versus minimally 
invasive direct coronary artery bypass surgery in the management of patients with 
proximal left anterior descending coronary artery stenosis were recently reported and 
drug-eluting stent implantation resulted in lower average number of hospital stays and 
similar postoperative complications. Ongoing trials should further clarify the diver-
gent information streams in this comparison.
I N T R O D U C T I O N
The potential for multivessel percutaneous coronary intervention (PCI) to be a 
competitor of coronary artery bypass graft surgery (CABG) early on, led to randomi-
zed trials demonstrating equivalent survival outcomes for balloon PCI compared with 
CABG [1]. However, patients undergoing balloon PCI frequently required additional 
revascularization later on compared with CABG patients. More recently the impact 
of coronary stents, with their potential for more durable revascularization, has been 
investigated [2-6]. Data from the Arterial Revascularization Therapies Study (ARTS) 
trial, which randomly assigned more than 1,200 patients with multivessel disease to 
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bare metal stenting or CABG, demonstrated a nearly 20% 
absolute reduction in the need for late revascularization in the 
stented patients compared with earlier balloon PCI studies [7]. 
Overall, 1-year mortality was not different between PCI using 
one or more bare metal stents and CABG. However, one of 
the major limitations of bare metal stents is in-stent restenosis. 
In-stent restenosis has been recognized as very difficult to 
manage, with a repeat restenosis rate of 50%, regardless of the 
angioplasty device used [8]. Despite an exhaustive search for 
an effective pharmacotherapy to treat or prevent restenosis, 
hundreds of clinical trials have failed to identify a pharmaco-
logic agent with proven therapeutic benefit. Experience with 
systemically administered drugs, such as antiplatelet agents, 
anticoagulants, calcium-channel blockers, angiotensin con-
verting enzyme inhibitors, cholesterol-lowering agents, and 
antioxidants, has proven almost universally negative [8].
Since approval of the first drug-eluting stent (DES), 
referrals for stenting have increased by more than 40%, and 
correspondingly, bypass surgery rates have begun to decline 
[9]. The early encouraging results and less invasive nature of 
DES coupled with the trauma involved in surgical access and 
conduit harvest, the systemic inflammatory response associ-
ated with cardiopulmonary bypass, the threat of postopera-
tive neurocognitive dysfunction, and vein graft attrition has 
resulted in many physicians going at great lengths to avoid 
recommending surgical revascularization to their patients .
A great enthusiasm has been created among several inter-
ventionalists that in the future, CABG will be of limited value 
and applied only to selected patients not amenable to PCI. 
Although this may become a reality, some concerns regarding 
long-term efficacy and long-term safety of DES, such as late 
thrombosis, late stent malapposition, aneurysm formation, 
edge effect, need to be definitely resolved [10]. This review 
article evaluates current status of DES and their possible im-
pact on the practice of coronary artery bypass surgery.
S U B S T A N C E S  F O R  D R U G - E L U T I N G  
S T E N T S
More than 40 substances, some that inhibit thrombotic, 
inflammatory, proliferative, or migratory processes and 
some that enhance endothelial healing, have been or are in 
the process of being evaluated as possible agents for DES 
[19,20]. Sirolimus, an immunosuppressant used in solid organ 
transplantation, has been found to delay endothelialization of 
stented surfaces. Sirolimus-eluting stents (SES) are coated 
with 140 ìg/cm of sirolimus, which is released over either 14 or 
28 days. Paclitaxel, a cancer chemotherapeutic agent used to 
treat ovarian and breast tumors, also has been found to delay 
healing processes. Paclitaxel-eluting stents (PES) are coated 
with 3 ìg/mm of paclitaxel, which is released over at least 10 
days. Both SES and PES are at present the only DES that have 
FDA approval for use in de novo stenotic lesions less than 28 
mm in length in native coronary arteries with reference vessel 
diameters between 2.5 and 3.5 mm.
R A N D O M I Z E D  C O N T R O L L E D  
T R I A L S  O F  D E S
Analysis of published randomized controlled trials com-
paring sirolimus-eluting stents (SES) or paclitaxel-eluting 
stents (PES) with bare metal stents shows that restenosis rate 
on routine follow-up angiography was substantially lower with 
DES than with bare metal stents, with consequent reductions 
in rates of target-lesion revascularization and major adverse 
cardiac events [11-18]. These effects were observed with SES 
and polymeric PES. In general, the trials of DES with sirolimus 
or paclitaxel were well conducted with clinical follow-up rates 
of more than 90%. Follow-up quantitative coronary angiogra-
phy was done in 43% to 97% of enrolled patients 6 to 9 months 
after the index PCI with intravascular ultrasound done in 17% 
to 100% patients in 7 of the 11 randomized controlled trials. 
Most trials were designed to assess the medium-term (6 to 12 
months after index PCI) efficacy of DES at decreasing angio-
graphic restenosis or clinical events. The inclusion criteria 
of all the trials specified that enrolled patients had de-novo 
(not restenotic) lesions in a native coronary artery with the 
exception of TAXUS I trial. Multilesion PCI with DES was 
not permitted in any trial. Patients with a recent myocardial 
infarction or a low ejection fraction were also excluded. Preva-
lence of diabetes ranged from 14% to 31%. Lesion lengths 
and reference-vessel diameters of the treated vessels varied 
between the trials, although in general the stented lesions were 
intermediate in length in medium-caliber vessels. The TAXi 
trial is the only trial to date that recruited patients represent-
ing real world interventional cardiology practice to evaluate 
whether a PES or an SES is superior in daily practice [19]. A 
total of 202 patients were included in this trial. One hundred 
patients received a PES and 102 received an SES. Procedural 
success was 99% in both groups. Incidence of major adverse 
cardiac events at follow-up (mean, 7±2 months) was 4% with 
the PES and 6% with the SES (p=0.8). The need for target 
lesion revascularization was very low in both groups (1% with 
the PES and 3% with the SES), confirming that the high suc-
cess rate obtained with both stents in randomized trials can 
be replicated in routine clinical practice.
R E A L  W O R L D  P R A C T I C E  O F  D E S
The findings from RESEARCH (Rapamycin Eluting Stent 
Evaluated At Rotterdam Cardiology Hospital) registry—the 
first large-scale registry of unrestricted use of SES—extend 
our knowledge about the clinical efficacy of SES in complex 
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patient subsets. Approximately 68% of patients included in 
the registry would have been excluded from the earlier clinical 
trials (eg, patients with previous coronary surgery, patients 
admitted with acute myocardial infarction, and those with 
multivessel stenting, among other high-risk characteristics). 
A 1-year follow-up comparative analysis of consecutive pa-
tients with de novo lesions (n=508) treated exclusively with 
SES and 450 patients who received bare stents in the period 
just before the introduction of DES revealed that patients in 
the SES group more frequently had multivessel disease, more 
type C lesions, received more stents, and had more bifurcation 
stenting [20]. At 1 year, the cumulative rate of major adverse 
cardiac events (death, myocardial infarction, or target vessel 
revascularization) was 9.7% in the SES group and 14.8% in 
the pre-SES group (hazard ratio [HR], 0.62, 95% confidence 
interval [CI]: 0.44 to 0.89; p=0.008). The 1-year risk of clini-
cally driven target vessel revascularization in the SES group 
and in the pre-SES group was 3.7% versus 10.9%, respec-
tively (HR, 0.35, 95% CI: 0.21 to 0.57; p=0.001). In three 
separate reports, RESEARCH investigators have shown DES 
implantation as highly effective for focal in-stent restenosis 
[21] and a promising and safe strategy for left main coronary 
artery lesions [22] and for patients with ST-elevation acute 
myocardial infarction [23]. More importantly, RESEARCH 
registry provides unique insights into the technical aspects of 
stent deployment techniques. Implantation of SES was always 
performed at high pressures (more than 12 atmospheres), and 
post-dilatation was liberally performed to achieve optimum 
angiographic results. Care was taken to avoid vessel injury 
beyond the stented area, and post-dilatation was performed 
with balloons shorter than the stent length. The number of 
stents, the total stented length, and the utilization of longer 
stents were higher in the SES group than in the bare stent 
group, which reflects an attempt of the operators to avoid geo-
graphical miss and cover the entire diseased segment with the 
DES (ie, “from normal tissue to normal tissue”)—the “longer 
is better” philosophy.
I M P A C T  O F  D E S  O N  V O L U M E  
O F  C O R O N A R Y  A R T E R Y  B Y P A S S  
S U R G E R Y
Treatment choices and treatment patterns for coronary 
artery disease have changed over the past several years, and 
are likely to evolve further in the next few years. Since the 
emergence of encouraging short-term and midterm outcomes 
of DES from randomized controlled trials and real world reg-
istries, there has been much discussion in the cardiovascular 
community regarding the potential impact of this revolution-
ary new technology on coronary bypass surgery volume. 
Many cardiologists and physicians have become reluctant 
to recommend surgical revascularization in the present era 
of DES partly from the fact that CABG is associated with a 
high up-front mortality and significant morbidity. However, 
in experienced centers available data indicate that mortality 
for isolated CABG should range from 1.2% to 1.7% [24]. At 
the same time, recent advances in the form of off-pump coro-
nary artery bypass surgery and MIDCABG have significantly 
reduced the morbidity associated with CABG [25]. It is gener-
ally accepted that left internal mammary artery (LIMA) to 
left anterior descending coronary artery (LAD) grafts are a 
durable and effective treatment for coronary artery disease 
with 95% of these grafts being widely patent 10 years after their 
construction, and that their successful construction confers a 
survival benefit on the patient [26].
Despite these improved results, the expanding use of DES 
is expected to have a negative impact on CABG surgery vol-
ume. Some of this negative impact will be undoubtedly due 
to the simultaneous availability of effective medical therapy 
for what is clearly a chronic disease.
To date, results of only one randomised controlled trial 
comparing DES with minimally invasive direct coronary 
artery bypass graft surgery (MIDCABG) in patients with 
LAD stenosis have been published [17]. In this trial symp-
tomatic patients (n=189), with an isolated high-grade lesion 
(stenosis of >70% of the luminal diameter) in the proximal 
LAD coronary artery (from the ostium to the first diagonal 
branch), were randomly assigned to the DES group (n=119) 
and the MIDCABG group (n=70). During the 6-month fol-
low-up period, 1.7% (n=2) in the DES group needed repeated 
revascularization procedures for target lesion revasculariza-
tion compared with 5.9% (n=4) in the MIDCABG group 
(p=0.196). The rates of death and myocardial infarction were 
similar in both groups (DES 0.0% [n=0] versus MIDCABG 
2.9% [n=2], p=0.135; DES 1.7% [n=2] versus MIDCABG 
2.9% [n=2], p=0.627; respectively) during 6 months of follow-
up. In-hospital length of stay was significantly shorter in the 
DES group compared with the MIDCABG group (5.8±2.1 
days versus 8.9±2.6 days; p=0.001). Implantation of DES 
and MIDCABG surgery showed similar rates of myocardial 
infarction, the need for repeated revascularization, and death 
during 6 months of follow-up. However, DES implantation 
resulted in lower average number of hospital stays and similar 
postoperative complications.
ARTS II study, which was designed to assess the efficacy 
of the SES in patients (n=607) with multivessel coronary ar-
tery disease compared with those of the surgical (n=605) and 
PCI (n=600) arm of the ARTS I study, as measured by major 
adverse cardiac and cerebrovascular event-free survival at 1 
year, provided us a better comparison of DES and CABG. The 
one year survival rate was 99% and the composite endpoint 
of MACCE-free survival 89.5% which approached the results 
of surgery in ARTS I.
The results of new randomised trials will further clarify the 
optimal method for treating patients with multi-vessel disease 
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in the era of DES. The FREEDOM (Future Revasculariza-
tion Evaluation in Patients with Diabetes Mellitus: Optimal 
Management of Multi-vessel Disease) trial is an international, 
multi-center ongoing trial that randomly assigned 2,400 pa-
tients with multi-vessel coronary disease and diabetes mellitus 
to bypass surgery or SES implantation. The patients will be 
followed up for 5 years. The SYNTAX (SYNergy Between PCI 
with TAXUS and Cardiac Surgery) study has been designed 
to randomize approximately 1,500 patients with three-vessel 
disease or left main disease, or both, to bypass surgery or 
multi-vessel PCI with the TAXUS stent.
A parallel registry for patients not enrolled is also planned 
for both studies. Hopefully, these trials will provide important 
information to guide the choice of the optimal revasculariza-
tion strategy for patients with multi-vessel disease.
P O T E N T I A L  D R A W B A C K S ,  C O N C E R N S ,  
A N D  U N R E S O L V E D  I S S U E S  R E L A T E D  
T O  D E S
The enthusiasm over DES is nearly universal among 
interventional cardiologists, and the promise of the virtual 
elimination of restenosis may force us to redefine the prac-
tice of cardiology. However, there are some drawbacks such 
as the late “catch-up” phenomenon, or stent thrombosis. A 
valid concern is that in the attempt to reduce restenosis fur-
ther to near zero, it is most important to consider also safety 
issues first [27-29]. Whereas restenosis has not been shown 
to be the major contributor to survival, the complications of 
acute vessel closure markedly reduce the long-term survival 
of patients. Therefore, any efforts to control restenosis, by 
modifying stent deployment techniques, must be balanced by 
an avoidance of any increase in complication rates. Another 
important issue is the cost for the unrestricted use of DES as 
an alternative to CABG.
I M P L I C A T I O N S  O F  I N C R E A S I N G  D E S  
U S E  F O R  C A R D I A C  S U R G E R Y
Cardiac surgeons must be aware of the potential risk of 
increased postoperative bleeding in this high-risk group of 
patients all of whom receive anticoagulation and antiplatelet 
medication during PCI. Modification of surgical techniques 
such as avoiding cardiopulmonary bypass and performing 
myocardial revascularization off-pump in patients who have 
received anticoagulants such as clopidogrel may theoretically 
reduce the incidence of postoperative bleeding and reduce 
the morbidity associated with need for re-exploration and 
transfusion of blood products.
In these rapidly changing times of catheter-based coronary 
interventions perhaps integrated (“hybrid”) coronary revascu-
larization of patients with multi-vessel coronary artery disease 
may be an alternative approach. This combined procedure 
is believed to offer the best of both worlds, MIDCABG and 
DES.
C O N C L U S I O N S
Despite our excitement about DES, we must remember 
that symptomatic atherosclerosis will be treated adequately 
with DES but not cured. If CABG ends up in the textbook 
of outdated procedures, in all likelihood it will be not only 
because of advances in interventional cardiology but also in 
the understanding and prevention of atherosclerosis. For now 
as well as the near future, it will perhaps be more prudent to 
look at DES and CABG as complementary therapies rather 
than rival techniques for myocardial revascularization.
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